Sigma receptors and substance use disorders

Advances in Experimental Medicine and Biology

Volumn 964, Issue , 2017, Pages 177-199

  Sabino, Valentina ^a   Hicks, Callum ^a   Cottone, Pietro ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; Alcohol OR Ethanol; Alcoholism; Cocaine; Drug abuse OR Abused drug; Methamphetamine; Psychostimulant; Withdrawal

Indexed keywords

ALCOHOL; COCAINE; METHAMPHETAMINE; MIDOMAFETAMINE; OPIATE ANTAGONIST; PSYCHEDELIC AGENT; SIGMA OPIATE RECEPTOR; SIGMA OPIATE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL SYNDROME; ALCOHOLISM; ARTICLE; COCAINE DEPENDENCE; COGNITIVE DEFECT; DRUG DEPENDENCE; DRUG SEEKING BEHAVIOR; HUMAN; LOCOMOTION; METHAMPHETAMINE DEPENDENCE; MIDOMAFETAMINE DEPENDENCE; MOLECULAR PATHOLOGY; NEUROSCIENCE; NEUROTOXICITY; NONHUMAN; PROTEIN FUNCTION; REINFORCEMENT; RELAPSE; REWARD; SEDATION; ANIMAL; BEHAVIOR, ADDICTIVE; METABOLISM; NEUROTOXICITY SYNDROMES; SUBSTANCE-RELATED DISORDERS;

ANIMALS; BEHAVIOR, ADDICTIVE; HUMANS; NEUROTOXICITY SYNDROMES; RECEPTORS, SIGMA; SUBSTANCE-RELATED DISORDERS;

EID: 85015929014     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-50174-1_13     Document Type: Article

References (183)

1. United Nations (2012) United Nations Office on Drugs and Crime (UNODC) World drug report. United Nations, New York
2. World Health Organization (2014) Global status report on alcohol and health. World Health Organization, Geneva
3. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Washington, DC
4. Volkow ND, Koob GF, McLellan AT (2016) Neurobiologic advances from the brain disease model of addiction. N Engl J Med 374(4):363–371. doi:10.1056/NEJMra1511480. PubMed PMID: 26816013
5. Goldstein A (2001) Addiction: from biology to drug policy, 2nd edn. Oxford University Press, New York
6. Volkow ND, Morales M (2015) The brain on drugs: from reward to addiction. Cell 162(4):712–725. doi:10.1016/j.cell.2015.07.046 PubMed PMID: 26276628
7. Vadivelu N, Mitra S, Kaye AD, Urman RD (2014) Perioperative analgesia and challenges in the drug-addicted and drug-dependent patient. Best Pract Res Clin Anaesthesiol 28(1):91–101
8. Degenhardt L, Hall W (2012) Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 379(9810):55–70. doi:10.1016/S0140-6736(11)61138-0 PubMed PMID: 22225671
9. UNODC (2012) UNODC (United Nations Office on Drugs and Crime) World drug report. UNODC, New York
10. Pascual-Leone A, Dhuna A, Altafullah I, Anderson DC (1990) Cocaine-induced seizures. Neurology 40(3 Pt 1):404–407 PubMed PMID: 2107459
11. Sporer KA, Firestone J (1997) Clinical course of crack cocaine body stuffers. Ann Emerg Med 29(5):596–601 PubMed PMID: 9140242
12. Zagnoni PG, Albano C (2002) Psychostimulants and epilepsy. Epilepsia 43(Suppl 2):28–31 PubMed PMID: 11903480
13. Sharkey J, Glen KA, Wolfe S, Kuhar MJ (1988) Cocaine binding at sigma receptors. EurJPharmacol. 149(1–2):171–174 PubMed PMID: 168
14. Lever JR, Fergason-Cantrell EA, Watkinson LD, Carmack TL, Lord SA, Xu R, Miller DK, Lever SZ (2016) Cocaine occupancy of sigma1 receptors and dopamine transporters in mice. Synapse 70(3):98–111. doi:10.1002/syn.21877 PubMed PMID: 26618331; PMCID: 4724290
15. Matsumoto RR, McCracken KA, Pouw B, Zhang Y, Bowen WD (2002) Involvement of sigma receptors in the behavioral effects of cocaine: evidence from novel ligands and antisense oligodeoxynucleotides. Neuropharmacology 42(8):1043–1055 Epub 2002/07/20. PubMed PMID: 12128006
16. Ritz MC, George FR (1993) Cocaine-induced seizures and lethality appear to be associated with distinct central nervous system binding sites. J Pharmacol Exp Ther 264(3):1333–1343 Epub 1993/03/01. PubMed PMID: 8450469
17. Ramamoorthy JD, Ramamoorthy S, Mahesh VB, Leibach FH, Ganapathy V (1995) Cocaine-sensitive sigma-receptor and its interaction with steroid hormones in the human placental syncytiotrophoblast and in choriocarcinoma cells. Endocrinology 136(3):924–932. doi:10.1210/endo.136.3.7867601 PubMed PMID: 7867601
18. Spiehler VR, Reed D (1985) Brain concentrations of cocaine and benzoylecgonine in fatal cases. J Forensic Sci 30(4):1003–1011 Epub 1985/10/01. PubMed PMID: 4067533
19. Mittleman RE, Wetli CV (1984) Death caused by recreational cocaine use. An update. JAMA 252(14):1889–1893 Epub 1984/10/12. PubMed PMID: 6471319
20. Navarro G, Moreno E, Bonaventura J, Brugarolas M, Farre D, Aguinaga D, Mallol J, Cortes A, Casado V, Lluis C, Ferre S, Franco R, Canela E, McCormick PJ (2013) Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers. PLoS One 8(4):e61245. doi:10.1371/journal.pone.0061245 PubMed PMID: 23637801; PMCID: 3630156
21. Kourrich S, Hayashi T, Chuang JY, Tsai SY, Su TP, Bonci A (2013) Dynamic interaction between sigma-1 receptor and Kv1.2 shapes neuronal and behavioral responses to cocaine. Cell 152(1–2):236–247 Epub 2013/01/22. doi: 10.1016/j.cell.2012.12.004. PubMed PMID: 23332758
22. Liu Y, Chen GD, Lerner MR, Brackett DJ, Matsumoto RR (2005) Cocaine up-regulates Fra-2 and sigma-1 receptor gene and protein expression in brain regions involved in addiction and reward. J Pharmacol Exp Ther 314(2):770–779 Epub 2005/05/10. doi: 10.1124/jpet.105.084525. PubMed PMID: 15879001
23. Tsai SY, Chuang JY, Tsai MS, Wang XF, Xi ZX, Hung JJ, Chang WC, Bonci A, Su TP (2015) Sigma-1 receptor mediates cocaine-induced transcriptional regulation by recruiting chromatin-remodeling factors at the nuclear envelope. Proc Natl Acad Sci U S A 112(47):E6562–E6570. doi:10.1073/pnas.1518894112 PubMed PMID: 26554014; PMCID: 4664336
24. Robson MJ, Noorbakhsh B, Seminerio MJ, Matsumoto RR (2012) Sigma-1 receptors: potential targets for the treatment of substance abuse. Curr Pharm Des 18(7):902–919 Epub 2012/02/01. PubMed PMID: 22288407
25. Matsumoto RR, Nguyen L, Kaushal N, Robson MJ (2014) Sigma (sigma) receptors as potential therapeutic targets to mitigate psychostimulant effects. Adv Pharmacol 69:323–386. doi:10.1016/B978-0-12-420118-7.00009-3 PubMed PMID: 24484982
26. Katz JL, Hong WC, Hiranita T, Su TP (2016) A role for sigma receptors in stimulant self-administration and addiction. Behav Pharmacol 27(2–3 Spec Issue):100–115. doi:10.1097/FBP.0000000000000209 PubMed PMID: 26650253; PMCID: 4779716
27. Underlying Cause of Death 1999–2014 [Internet] 2015 [cited 05/08/2016]. Available from: http://wonder. cdc.gov/ucd-icd10.html
28. Matsumoto RR, McCracken KA, Friedman MJ, Pouw B, De Costa BR, Bowen WD (2001) Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice. Eur J Pharmacol 419(2–3):163–174 PubMed PMID: 11426838
29. Matsumoto RR, McCracken KA, Pouw B, Miller J, Bowen WD, Williams W, De Costa BR (2001) N-alkyl substituted analogs of the sigma receptor ligand BD1008 and traditional sigma receptor ligands affect cocaine-induced convulsions and lethality in mice. Eur J Pharmacol 411(3):261–273 PubMed PMID: 11164383
30. Kaushal N, Robson MJ, Vinnakota H, Narayanan S, Avery BA, McCurdy CR, Matsumoto RR (2011) Synthesis and pharmacological evaluation of 6-acetyl- 3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl) benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents. AAPS J 13(3):336–346. doi:10.1208/s12248-011-9274-9 PubMed PMID: 21494909; PMCID: 3160158
31. Matsumoto RR, Pouw B, Mack AL, Daniels A, Coop A (2007) Effects of UMB24 and (+/−)-SM 21, putative sigma2-preferring antagonists, on behavioral toxic and stimulant effects of cocaine in mice. Pharmacol Biochem Behav 86(1):86–91. doi:10.1016/j.pbb.2006.12.011 PubMed PMID: 17241657; PMCID: 1892169
32. Xu YT, Kaushal N, Shaikh J, Wilson LL, Mesangeau C, McCurdy CR, Matsumoto RR (2010) A novel substituted piperazine, CM156, attenuates the stimulant and toxic effects of cocaine in mice. J Pharmacol Exp Ther 333(2):491–500. doi:10.1124/jpet.109.161398 PubMed PMID: 20100904; PMCID: 2872963
33. Matsumoto RR, Potelleret FH, Mack A, Pouw B, Zhang Y, Bowen WD (2004) Structure-activity comparison of YZ-069, a novel sigma ligand, and four analogs in receptor binding and behavioral studies. Pharmacol Biochem Behav 77(4):775–781. doi:10.1016/j.pbb.2004.01.014 PubMed PMID: 15099923
34. Liu Y, Matsumoto RR (2008) Alterations in fos-related antigen 2 and sigma1 receptor gene and protein expression are associated with the development of cocaine-induced behavioral sensitization: time course and regional distribution studies. J Pharmacol Exp Ther 327(1):187–195 Epub 2008/07/02. doi: 10.1124/jpet.108.141051. PubMed PMID: 18591217
35. Barr JL, Deliu E, Brailoiu GC, Zhao P, Yan G, Abood ME, Unterwald EM, Brailoiu E (2015) Mechanisms of activation of nucleus accumbens neurons by cocaine via sigma-1 receptor-inositol 1,4,5-trisphosphate-transient receptor potential canonical channel pathways. Cell Calcium 58(2):196–207. doi:10.1016/j.ceca.2015.05.001 PubMed PMID: 26077147; PMCID: 4501893
36. Goldstein SR, Matsumoto RR, Thompson TL, Patrick RL, Bowen WD, Walker JM (1989) Motor effects of two sigma ligands mediated by nigrostriatal dopamine neurons. Synapse 4(3):254–258 Epub 1989/01/01. doi: 10.1002/syn.890040311. PubMed PMID: 2558420
37. Bastianetto S, Rouquier L, Perrault G, Sanger DJ (1995) DTG-induced circling behaviour in rats may involve the interaction between sigma sites and nigro-striatal dopaminergic pathways. Neuropharmacology 34(3):281–287 Epub 1995/03/01. PubMed PMID: 7630482
38. Bardo MT, Bevins RA (2000) Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology 153(1):31–43 PubMed PMID: 11255927
39. Romieu P, Martin-Fardon R, Maurice T (2000) Involvement of the sigma1 receptor in the cocaine-induced conditioned place preference. Neuroreport 11(13):2885–2888 Epub 2000/09/28. PubMed PMID: 11006959
40. Romieu P, Phan VL, Martin-Fardon R, Maurice T (2002) Involvement of the sigma(1) receptor in cocaine-induced conditioned place preference: possible dependence on dopamine uptake blockade. Neuropsychopharmacology 26(4):444–455 Epub 2002/04/03. doi: 10.1016/S0893-133X(01)00391-8. PubMed PMID: 11927169
41. Sage AS, Vannest SC, Fan KH, Will MJ, Lever SZ, Lever JR, Miller DK (2013) N-Phenylpropyl-N’-(3- methoxyphenethyl)piperazine (YZ-185) attenuates the conditioned-rewarding properties of cocaine in mice. ISRN Pharmacol 2013:546314. doi:10.1155/2013/546314 PubMed PMID: 24089641; PMCID: 3780704
42. Xu YT, Robson MJ, Szeszel-Fedorowicz W, Patel D, Rooney R, McCurdy CR, Matsumoto RR (2012) CM156, a sigma receptor ligand, reverses cocaine-induced place conditioning and transcriptional responses in the brain. Pharmacol Biochem Behav 101(1):174–180. doi:10.1016/j.pbb.2011.12.016 PubMed PMID: 22234290; PMCID: 3726055
43. Romieu P, Meunier J, Garcia D, Zozime N, Martin-Fardon R, Bowen WD, Maurice T (2004) The sigma1 (sigma1) receptor activation is a key step for the reactivation of cocaine conditioned place preference by drug priming. Psychopharmacology 175(2):154–162 Epub 2004/02/27. doi: 10.1007/s00213-004-1814-x. PubMed PMID: 14985920
44. Romieu P, Martin-Fardon R, Bowen WD, Maurice T (2003) Sigma 1 receptor-related neuroactive steroids modulate cocaine-induced reward. J Neurosci 23(9):3572–3576 Epub 2003/05/09. PubMed PMID: 12736327
45. Fritz M, Klement S, El Rawas R, Saria A, Zernig G (2011) Sigma1 receptor antagonist BD1047 enhances reversal of conditioned place preference from cocaine to social interaction. Pharmacology 87(1–2):45–48. doi:10.1159/000322534 PubMed PMID: 21196793
46. Mori T, Rahmadi M, Yoshizawa K, Itoh T, Shibasaki M, Suzuki T (2014) Inhibitory effects of SA4503 on the rewarding effects of abused drugs. Addict Biol 19(3):362–369. doi:10.1111/j.1369-1600.2012.00488.x PubMed PMID: 22934790
47. Rodvelt KR, Lever SZ, Lever JR, Blount LR, Fan KH, Miller DK (2011) SA 4503 attenuates cocaine-induced hyperactivity and enhances methamphetamine substitution for a cocaine discriminative stimulus. Pharmacol Biochem Behav 97(4):676–682. doi:10.1016/j.pbb.2010.11.016 PubMed PMID: 21115033; PMCID: 3023454
48. Ukai M, Mori E, Kameyama T (1997) Modulatory effects of morphine, U-50488H and 1,3-di-(2-tolyl) guanidine on cocaine-like discriminative stimulus in the rat using two-choice discrete-trial avoidance paradigm. Methods Find Exp Clin Pharmacol 19(8):541–546 Epub 1998/01/27. PubMed PMID: 9442477
49. Hiranita T, Soto PL, Tanda G, Katz JL (2011) Lack of cocaine-like discriminative-stimulus effects of sigmareceptor agonists in rats. Behav Pharmacol 22(5–6):525–530. doi:10.1097/FBP.0b013e328349ab22 PubMed PMID: 21808192; PMCID: 3666342
50. Martin-Fardon R, Maurice T, Aujla H, Bowen WD, Weiss F (2007) Differential effects of sigma1 receptor blockade on self-administration and conditioned reinstatement motivated by cocaine vs natural reward. Neuropsychopharmacology 32(9):1967–1973 Epub 2007/02/03. doi: 10.1038/sj.npp.1301323. PubMed PMID: 17268407
51. Hiranita T, Soto PL, Tanda G, Katz JL (2010) Reinforcing effects of sigma-receptor agonists in rats trained to self-administer cocaine. J Pharmacol Exp Ther 332(2):515–524
52. Epub 2009/11/07. doi: 10.1124/jpet.109.159236. PubMed PMID: 19892920; PMCID: 2812106
53. Hiranita T, Soto PL, Kohut SJ, Kopajtic T, Cao J, Newman AH, Tanda G, Katz JL (2011) Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and sigma receptors. J Pharmacol Exp Ther 339(2):662–677. doi:10.1124/jpet.111.185025 PubMed PMID: 21859929; PMCID: 3199989
54. Hiranita T, Mereu M, Soto PL, Tanda G, Katz JL (2013) Self-administration of cocaine induces dopamine-independent self-administration of sigma agonists. Neuropsychopharmacology 38(4):605–615. doi:10.1038/npp.2012.224 PubMed PMID: 23187725; PMCID: 3572457
55. Garces-Ramirez L, Green JL, Hiranita T, Kopajtic TA, Mereu M, Thomas AM, Mesangeau C, Narayanan S, McCurdy CR, Katz JL, Tanda G (2011) Sigma receptor agonists: receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis. Biol Psychiatry 69(3):208–217. doi:10.1016/j.biopsych.2010.07.026 PubMed PMID: 20950794; PMCID: 3015019
56. Anglin MD, Burke C, Perrochet B, Stamper E, Dawud-Noursi S (2000) History of the methamphetamine problem. J Psychoactive Drugs 32(2):137–141. doi:10.1080/02791072.2000.10400221 PubMed PMID: 10908000
57. Kuo CJ, Liao YT, Chen WJ, Tsai SY, Lin SK, Chen CC (2011) Causes of death of patients with methamphetamine dependence: a record-linkage study. Drug Alcohol Rev 30(6):621–628. doi:10.1111/j.1465-3362.2010.00255.x PubMed PMID: 21355920; PMCID: 3117111
58. Kaye S, McKetin R, Duflou J, Darke S (2007) Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction 102(8):1204–1211. doi:10.1111/j.1360-0443.2007.01874.x PubMed PMID: 17565561
59. Zapata LB, Hillis SD, Marchbanks PA, Curtis KM, Lowry R (2008) Methamphetamine use is independently associated with recent risky sexual behaviors and adolescent pregnancy. J Sch Health 78(12):641–648. doi:10.1111/j.1746-1561.2008.00360.x PubMed PMID: 19000240
60. Gibson DR, Leamon MH, Flynn N (2002) Epidemiology and public health consequences of methamphetamine use in California’s Central Valley. J Psychoactive Drugs 34(3):313–319. doi:10.1080/02791072.2002.10399969 PubMed PMID: 12422943
61. Forrest DW, Metsch LR, LaLota M, Cardenas G, Beck DW, Jeanty Y (2010) Crystal methamphetamine use and sexual risk behaviors among HIV-positive and HIV-negative men who have sex with men in South Florida. J Urban Health 87(3):480–485. doi:10.1007/s11524-009-9422-z PubMed PMID: 20101468; PMCID: 2871089
62. Rawson RA, McCann MJ, Flammino F, Shoptaw S, Miotto K, Reiber C, Ling W (2006) A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction 101(2):267–274. doi:10.1111/j.1360-0443.2006.01312.x PubMed PMID: 16445555
63. Westover AN, Nakonezny PA, Haley RW (2008) Acute myocardial infarction in young adults who abuse amphetamines. Drug Alcohol Depend 96(1–2):49–56. doi:10.1016/j.drugalcdep.2008.01.027 PubMed PMID: 18353567; PMCID: 2533107
64. Haning W, Goebert D (2007) Electrocardiographic abnormalities in methamphetamine abusers. Addiction 102(Suppl 1):70–75. doi:10.1111/j.1360-0443.2006.01776.x PubMed PMID: 17493055
65. Westover AN, McBride S, Haley RW (2007) Stroke in young adults who abuse amphetamines or cocaine: a population-based study of hospitalized patients. Arch Gen Psychiatry 64(4):495–502. doi:10.1001/archpsyc.64.4.495 PubMed PMID: 17404126
66. Klasser GD, Epstein J (2005) Methamphetamine and its impact on dental care. Journal 71(10):759–762 PubMed PMID: 16324229
67. Radfar SR, Rawson RA (2014) Current research on methamphetamine: epidemiology, medical and psychiatric effects, treatment, and harm reduction efforts. Addict Health 6(3–4):146–154 PubMed PMID: 25984282; PMCID: 4354220
68. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, Grant I (2007) Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 17(3):275–297. doi:10.1007/s11065-007-9031-0 PubMed PMID: 17694436
69. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158(3):377–382. doi:10.1176/appi.ajp.158.3.377 PubMed PMID: 11229977
70. Simon SL, Domier C, Carnell J, Brethen P, Rawson R, Ling W (2000) Cognitive impairment in individuals currently using methamphetamine. Am J Addict/Am Acad Psychiatr Alcohol Addict 9(3):222–231 PubMed PMID: 11000918
71. Rippeth JD, Heaton RK, Carey CL, Marcotte TD, Moore DJ, Gonzalez R, Wolfson T, Grant I, Group H (2004) Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc 10(1):1–14. doi:10.1017/S1355617704101021 PubMed PMID: 14751002
72. Salo R, Flower K, Kielstein A, Leamon MH, Nordahl TE, Galloway GP (2011) Psychiatric comorbidity in methamphetamine dependence. Psychiatry Res 186(2–3):356–361. doi:10.1016/j.psychres.2010.09.014 PubMed PMID: 21055832; PMCID: 3058719
73. Cruickshank CC, Dyer KR (2009) A review of the clinical pharmacology of methamphetamine. Addiction 104(7):1085–1099
74. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ (2005) Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry 13(3):141–154. doi:10.1080/10673220591003605 PubMed PMID: 16020027
75. Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D, Iguchi M, Methamphetamine TP (2004) Psychiatric symptoms in methamphetamine users. Am J Addict 13(2):181–190. doi:10.1080/10550490490436055 PubMed PMID: 15204668
76. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson RA, Methamphetamine Treatment Project Corporate Authors (2010) Psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug Alcohol Rev 29(1):12–20. doi:10.1111/j.1465-3362.2009.00081.x PubMed PMID: 20078677; PMCID: 3772133
77. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R, Methamphetamine TP (2008) Identifying methamphetamine users at risk for major depressive disorder: findings from the methamphetamine treatment project at three-year followup. Am J Addict/Am Acad Psychiatr Alcohol Addict 17(2):99–102. doi:10.1080/10550490701861110 PubMed PMID: 18393051
78. McKetin R, McLaren J, Lubman DI, Hides L (2006) The prevalence of psychotic symptoms among methamphetamine users. Addiction 101(10):1473–1478. doi:10.1111/j.1360-0443.2006.01496.x PubMed PMID: 16968349
79. Iwanami A, Sugiyama A, Kuroki N, Toda S, Kato N, Nakatani Y, Horita N, Kaneko T (1994) Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan. A preliminary report. Acta Psychiatr Scand 89(6):428–432 PubMed PMID: 8085475
80. Ujike H, Sato M (2004) Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci 1025:279–287. doi:10.1196/annals.1316.035 PubMed PMID: 15542728
81. King M, Pan YX, Mei J, Chang A, Xu J, Pasternak GW (1997) Enhanced kappa-opioid receptor-mediated analgesia by antisense targeting the sigma1 receptor. Eur J Pharmacol 331(1):R5–R6 Epub 1997/07/16. PubMed PMID: 9274937
82. Brown JM, Riddle EL, Sandoval V, Weston RK, Hanson JE, Crosby MJ, Ugarte YV, Gibb JW, Hanson GR, Fleckenstein AE (2002) A single methamphetamine administration rapidly decreases vesicular dopamine uptake. J Pharmacol Exp Ther 302(2):497–501 Epub 2002/07/20. PubMed PMID: 12130707
83. Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE (2002) Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J Pharmacol Exp Ther 300(3):1093–1100 Epub 2002/02/28. PubMed PMID: 11861820
84. Riddle EL, Topham MK, Haycock JW, Hanson GR, Fleckenstein AE (2002) Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur J Pharmacol 449(1–2):71–74 Epub 2002/08/07. PubMed PMID: 12163108
85. Verrico CD, Miller GM, Madras BK (2007) MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology 189(4):489–503 Epub 2005/10/13. doi: 10.1007/s00213-005-0174-5. PubMed PMID: 16220332
86. Nguyen EC, McCracken KA, Liu Y, Pouw B, Matsumoto RR (2005) Involvement of sigma (σ) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies. Neuropharmacology 49(5):638–645 Epub 2005/06/09. doi: 10.1016/j.neuropharm.2005.04.016. PubMed PMID: 15939443
87. Hayashi T, Su TP (2007) Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 131(3):596–610 Epub 2007/11/06. doi: 10.1016/j.cell.2007.08.036. PubMed PMID: 17981125
88. Navarro G, Moreno E, Aymerich M, Marcellino D, McCormick PJ, Mallol J, Cortes A, Casado V, Canela EI, Ortiz J, Fuxe K, Lluis C, Ferre S, Franco R (2010) Direct involvement of sigma-1 receptors in the dopamine D1 receptor-mediated effects of cocaine. Proc Natl Acad Sci U S A 107(43):18676–18681. doi:10.1073/pnas.1008911107 PubMed PMID: 20956312; PMCID: 2972946
89. Jayanthi S, Deng X, Noailles PA, Ladenheim B, Cadet JL (2004) Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades. FASEB J 18(2):238–251. doi:10.1096/fj.03-0295com PubMed PMID: 14769818
90. Itzhak Y (1993) Repeated methamphetamine-treatment alters brain sigma receptors. Eur J Pharmacol 230(2):243–244
91. Stefanski R, Justinova Z, Hayashi T, Takebayashi M, Goldberg SR, Su TP (2004) Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: a study with yoked controls. Psychopharmacology 175(1):68–75 Epub 2004/03/19. doi: 10.1007/s00213-004-1779-9. PubMed PMID: 15029471
92. Hayashi T, Justinova Z, Hayashi E, Cormaci G, Mori T, Tsai SY, Barnes C, Goldberg SR, Su TP (2010) Regulation of sigma-1 receptors and endoplasmic reticulum chaperones in the brain of methamphetamine self-administering rats. J Pharmacol Exp Ther 332(3):1054–1063 Epub 2009/11/27. doi: jpet.109.159244 [pii] 10.1124/jpet.109.159244. PubMed PMID: 19940104; PMCID: 2835445
93. Bowyer JF, Davies DL, Schmued L, Broening HW, Newport GD, Slikker W Jr, Holson RR (1994) Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 268(3):1571–1580 PubMed PMID: 8138969
94. Kaushal N, Seminerio MJ, Robson MJ, McCurdy CR, Matsumoto RR (2013) Pharmacological evaluation of SN79, a sigma (σ) receptor ligand, against methamphetamine-induced neurotoxicity in vivo. Eur Neuropsychopharmacol 23(8):960–971
95. Kaushal N, Seminerio MJ, Shaikh J, Medina MA, Mesangeau C, Wilson LL, McCurdy CR, Matsumoto RR (2011) CM156, a high affinity sigma ligand, attenuates the stimulant and neurotoxic effects of methamphetamine in mice. Neuropharmacology 61(5–6):992–1000. doi:10.1016/j.neuropharm.2011.06.028 PubMed PMID: 21762711; PMCID: 3615888
96. Robson MJ, Seminerio MJ, McCurdy CR, Coop A, Matsumoto RR (2013) Sigma receptor antagonist attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature modulation. Pharmacol Rep 65(2):343–349 PubMed PMID: 23744418
97. Seminerio MJ, Hansen R, Kaushal N, Zhang HT, McCurdy CR, Matsumoto RR (2013) The evaluation of AZ66, an optimized sigma receptor antagonist, against methamphetamine-induced dopaminergic neurotoxicity and memory impairment in mice. Int J Neuropsychopharmacol 16(5):1033–1044. doi:10.1017/S1461145712000831 PubMed PMID: 22932447
98. Seminerio MJ, Kaushal N, Shaikh J, Huber JD, Coop A, Matsumoto RR (2011) Sigma (sigma) receptor ligand, AC927 (N-phenethylpiperidine oxalate), attenuates methamphetamine-induced hyperthermia and serotonin damage in mice. Pharmacol Biochem Behav 98(1):12–20. doi:10.1016/j.pbb.2010.11.023 PubMed PMID: 21130800; PMCID: 3726056
99. Seminerio MJ, Robson MJ, McCurdy CR, Matsumoto RR (2012) Sigma receptor antagonists attenuate acute methamphetamine-induced hyperthermia by a mechanism independent of IL-1beta mRNA expression in the hypothalamus. Eur J Pharmacol 691(1–3):103–109. doi:10.1016/j.ejphar.2012.07.029 PubMed PMID: 22820108; PMCID: 3726051
100. Matsumoto RR, Shaikh J, Wilson LL, Vedam S, Coop A (2008) Attenuation of methamphetamine-induced effects through the antagonism of sigma (sigma) receptors: Evidence from in vivo and in vitro studies. Eur Neuropsychopharmacol 18(12):871–881. doi:10.1016/j.euroneuro.2008.07.006 PubMed PMID: 18755577; PMCID: 2688716
101. Ricaurte GA, Schuster CR, Seiden LS (1980) Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res 193(1):153–163 PubMed PMID: 7378814
102. Seiden LS, Commins DL, Vosmer G, Axt K, Marek G (1988) Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: a regional analysis in nigrostriatal and mesolimbic projections. Ann N Y Acad Sci 537:161–172 PubMed PMID: 3059922
103. Krasnova IN, Cadet JL (2009) Methamphetamine toxicity and messengers of death. Brain Res Rev 60(2):379–407. doi:10.1016/j.brainresrev.2009.03.002 PubMed PMID: 19328213; PMCID: 2731235
104. RHalpin LE, Collins SA, Yamamoto BK (2014) Neurotoxicity of methamphetamine and 3,4-methylendioxymethamphetamine. Life Sci 97(1):37–44
105. Robson MJ, Turner RC, Naser ZJ, McCurdy CR, O’Callaghan JP, Huber JD, Matsumoto RR (2014) SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation. Exp Neurol 254:180–189
106. Kaushal N, Elliott M, Robson MJ, Iyer AK, Rojanasakul Y, Coop A, Matsumoto RR (2012) AC927, a sigma receptor ligand, blocks methamphetamine-induced release of dopamine and generation of reactive oxygen species in NG108–15 cells. Mol Pharmacol 81(3):299–308. doi:10.1124/mol.111.074120 PubMed PMID: 22101517; PMCID: 3286303
107. Moratalla R, Khairnar A, Simola N, Granado N, García-Montes JR, Porceddu PF, Tizabi Y, Costa G, Morelli M (2015) Amphetamine-related drugs neurotoxicity in humans and in experimental animals: main mechanisms. Prog Neurobiol. doi:10.1016/j.pneurobio.2015.09.011
108. Loftis JM, Janowsky A (2014) Neuroimmune basis of methamphetamine toxicity. Int Rev Neurobiol 118:165–197
109. Shah A, Silverstein PS, Singh DP, Kumar A (2012) Involvement of metabotropic glutamate receptor 5, AKT/PI3K signaling and NF-kB pathway in methamphetamine-mediated increase in IL-6 and IL-8 expression in astrocytes. J Neuroinflammation 9:52
110. Zhang Y, Lv X, Bai Y, Zhu X, Wu X, Chao J, Duan M, Buch S, Chen L, Yao H (2015) Involvement of sigma-1 receptor in astrocyte activation induced by methamphetamine via up-regulation of its own expression. J Neuroinflammation 12(1):29
111. Pu C, Vorhees CV (1993) Developmental dissociation of methamphetamine-induced depletion of dopaminergic terminals and astrocyte reaction in rat striatum. Dev Brain Res 72(2):325–328
112. Bevins RA, Peterson JL (2004) Individual differences in rats’ reactivity to novelty and the unconditioned and conditioned locomotor effects of methamphetamine. Pharmacol Biochem Behav 79(1):65–74. doi:10.1016/j.pbb.2004.06.002 PubMed PMID: 15388285
113. Kuczenski R, Segal DS, Melega WP, Lacan G, McCunney SJ (2009) Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge. Neuropsychopharmacology 34(11):2430–2441. doi:10.1038/npp.2009.73 PubMed PMID: 19571794; PMCID: 2778493
114. Maehara S, Hikichi H, Satow A, Okuda S, Ohta H (2008) Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia. Pharmacol Biochem Behav 91(1):140–149. doi:10.1016/j.pbb.2008.06.023 PubMed PMID: 18651995
115. Ujike H, Onoue T, Akiyama K, Hamamura T, Otsuki S (1989) Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization. Psychopharmacology 98(1):89–92 PubMed PMID: 2498964
116. Bhosale BB, Balsara JJ, Jadhav JH (1997) Effects of pentazocine on dopamine-dependent behaviours in mice. Indian J Exp Biol 35(5):448–450 PubMed PMID: 9378511
117. Kitanaka J, Kitanaka N, Tatsuta T, Hall FS, Uhl GR, Tanaka K, Nishiyama N, Morita Y, Takemura M (2009) Sigma1 receptor antagonists determine the behavioral pattern of the methamphetamine-induced stereotypy in mice. Psychopharmacology 203(4):781–792 Epub 2008/12/05. doi: 10.1007/s00213-008-1425-z. PubMed PMID: 19052726
118. Ujike H, Kanzaki A, Okumura K, Akiyama K, Otsuki S (1992) Sigma (σ) antagonist BMY 14802 prevents methamphetamine-induced sensitization. Life Sci 50(16):PL129–PPL34
119. Ujike H, Okumura K, Zushi Y, Akiyama K, Otsuki S (1992) Persistent supersensitivity of sigma receptors develops during repeated methamphetamine treatment. Eur J Pharmacol 211(3):323–328 PubMed PMID: 100
120. Rodvelt KR, Oelrichs CE, Blount LR, Fan K-H, Lever SZ, Lever JR, Miller DK (2011) The sigma receptor agonist SA4503 both attenuates and enhances the effects of methamphetamine. Drug Alcohol Depend 116(1):203–210 Epub 2011/02/01. doi: 10.1016/j.drugalcdep.2010.12.018. PubMed PMID: 21277708; PMCID: 3105201
121. Takahashi S, Miwa T, Horikomi K (2000) Involvement of sigma 1 receptors in methamphetamine-induced behavioral sensitization in rats. Neurosci Lett 289(1):21–24 PubMed PMID: 97
122. Gudelsky GA (1999) Biphasic effect of sigma receptor ligands on the extracellular concentration of dopamine in the striatum of the rat. J Neural Transm 106(9–10):849–856. doi:10.1007/s007020050205 PubMed PMID: 10599867
123. Moison D, De Deurwaerdere P, Cagnotto A, Marrazzo A, Prezzavento O, Ronsisvalle G, Mennini T, Spampinato U (2003) Intrastriatal administration of sigma ligands inhibits basal dopamine release in vivo. Neuropharmacology 45(7):945–953 PubMed PMID: 14573387
124. Meurs A, Clinckers R, Ebinger G, Michotte Y, Smolders I (2007) Sigma 1 receptor-mediated increase in hippocampal extracellular dopamine contributes to the mechanism of the anticonvulsant action of neuropeptide Y. Eur J Neurosci 26(11):3079–3092. doi:10.1111/j.1460-9568.2007.05911.x PubMed PMID: 18005069
125. Yamazaki Y, Ishioka M, Matsubayashi H, Amano T, Sasa M (2002) Inhibition by sigma receptor ligand, MS-377, of N-methyl- D-aspartate-induced currents in dopamine neurons of the rat ventral tegmental area. Psychopharmacology 161(1):64–69. doi:10.1007/s00213-002-1023-4 PubMed PMID: 11967632
126. Walker JM, Bowen WD, Walker FO, Matsumoto RR, De CB, Rice KC (1990) Sigma receptors: biology and function. Pharmacol Rev 42(4):355–402 PubMed PMID: 67
127. Brammer MK, Gilmore DL, Matsumoto RR (2006) Interactions between 3,4-methylenedioxymethamph etamine and sigma1 receptors. Eur J Pharmacol 553(1–3):141–145 Epub 2006/10/31. doi: 10.1016/j.ejphar.2006.09.038. PubMed PMID: 17070798; PMCID: 1780037
128. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J (2009) Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 373(9682):2223–2233. doi:10.1016/S0140-6736(09)60746-7 PubMed PMID: 19560604
129. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJ, Vos T (2013) Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382(9904):1575–1586. doi:10.1016/S0140-6736(13)61611-6 PubMed PMID: 23993280
130. Lobo IA, Harris RA (2008) GABA(A) receptors and alcohol. Pharmacol Biochem Behav 90(1):90–94. doi:10.1016/j.pbb.2008.03.006 PubMed PMID: 18423561; PMCID: 2574824
131. Santhakumar V, Wallner M, Otis TS (2007) Ethanol acts directly on extrasynaptic subtypes of GABAA receptors to increase tonic inhibition. Alcohol 41(3):211–221. doi:10.1016/j.alcohol.2007.04.011 PubMed PMID: 17591544; PMCID: 2040048
132. Mehta AK, Ticku MK (1988) Ethanol potentiation of GABAergic transmission in cultured spinal cord neurons involves gamma-aminobutyric acidA-gated chloride channels. J Pharmacol Exp Ther 246(2):558–564 PubMed PMID: 2457076
133. Suzdak PD, Schwartz RD, Skolnick P, Paul SM (1988) Alcohols stimulate gamma-aminobutyric acid receptor-mediated chloride uptake in brain vesicles: correlation with intoxication potency. Brain Res 444(2):340–345 PubMed PMID: 2834024
134. Sundstrom-Poromaa I, Smith DH, Gong QH, Sabado TN, Li X, Light A, Wiedmann M, Williams K, Smith SS (2002) Hormonally regulated alpha(4)beta(2) delta GABA(A) receptors are a target for alcohol. Nat Neurosci 5(8):721–722. doi:10.1038/nn888 PubMed PMID: 12118257; PMCID: 2887346
135. Wallner M, Hanchar HJ, Olsen RW (2003) Ethanol enhances alpha 4 beta 3 delta and alpha 6 beta 3 delta gamma-aminobutyric acid type A receptors at low concentrations known to affect humans. Proc Natl Acad Sci U S A 100(25):15218–15223. doi:10.1073/pnas.2435171100 PubMed PMID: 14625373; PMCID: 299963
136. Lima-Landman MT, Albuquerque EX (1989) Ethanol potentiates and blocks NMDA-activated single-channel currents in rat hippocampal pyramidal cells. FEBS Lett 247(1):61–67 PubMed PMID: 2468533
137. Wright JM, Peoples RW, Weight FF (1996) Single-channel and whole-cell analysis of ethanol inhibition of NMDA-activated currents in cultured mouse cortical and hippocampal neurons. Brain Res 738(2):249–256 PubMed PMID: 8955520
138. Phillips TJ, Shen EH (1996) Neurochemical bases of locomotion and ethanol stimulant effects. Int Rev Neurobiol 39:243–282 Epub 1996/01/01. PubMed PMID: 8894850
139. Maurice T, Casalino M, Lacroix M, Romieu P (2003) Involvement of the sigma 1 receptor in the motivational effects of ethanol in mice. Pharmacol Biochem Behav 74(4):869–876 Epub 2003/04/02. PubMed PMID: 12667901
140. Valenza M, DiLeo A, Steardo L, Cottone P, Sabino V (2015) Ethanol-related behaviors in mice lacking the sigma-1 receptor. Behav Brain Res. doi:10.1016/j.bbr.2015.10.013 [Epub ahead of print]
141. Cunningham CL, Noble D (1992) Conditioned activation induced by ethanol: role in sensitization and conditioned place preference. Pharmacol Biochem Behav 43(1):307–313 PubMed PMID: 1409816
142. Bhutada PS, Mundhada YR, Ghodki YR, Chaware P, Dixit PV, Jain KS, Umathe SN (2012) Influence of sigma-1 receptor modulators on ethanol-induced conditioned place preference in the extinction-reinstatement model. Behav Pharmacol 23(1):25–33 Epub 2011/12/06. doi: 10.1097/FBP.0b013e32834eafe6. PubMed PMID: 22139605
143. Miyatake R, Furukawa A, Matsushita S, Higuchi S, Suwaki H (2004) Functional polymorphisms in the sigma1 receptor gene associated with alcoholism. Biol Psychiatry 55(1):85–90
144. Cloninger CR, Bohman M, Sigvardsson S (1981) Inheritance of alcohol abuse: cross-fostering analysis of adopted men. Arch Gen Psychiatry 38(8):861–868
145. Prescott CA, Kendler KS (1999) Genetic and environmental contributions to alcohol abuse and dependence in a population-based sample of male twins. Am J Psychiatr 156(1):34–40
146. Sigvardsson S, Bohman M, Cloninger CR (1996) Replication of the stockholm adoption study of alcoholism: confirmatory cross-fostering analysis. Arch Gen Psychiatry 53(8):681–687
147. Colombo G, Lobina C, Carai MA, Gessa GL (2006) Phenotypic characterization of genetically selected Sardinian alcohol-preferring (sP) and -non-preferring (sNP) rats. Addict Biol 11(3–4):324–338 Epub 2006/09/12. doi: 10.1111/j.1369-1600.2006.00031.x. PubMed PMID: 16961762.
148. Blasio A, Valenza M, Iyer MR, Rice KC, Steardo L, Hayashi T, Cottone P, Sabino V (2015) Sigma-1 receptor mediates acquisition of alcohol drinking and seeking behavior in alcohol-preferring rats. Behav Brain Res 287:315–322. doi:10.1016/j.bbr.2015.03.065 PubMed PMID: 25848705; PMCID: 4424067
149. Sabino V, Cottone P, Zhao Y, Steardo L, Koob GF, Zorrilla EP (2009) Selective reduction of alcohol drinking in Sardinian alcohol-preferring rats by a sigma-1 receptor antagonist. Psychopharmacology 205(2):327–335 Epub 2009/05/15. doi: 10.1007/s00213-009-1548-x. PubMed PMID: 19440699; PMCID: 2748837
150. Cowen MS, Rezvani AH, Jarrott B, Lawrence AJ (1999) Ethanol consumption by Fawn-Hooded rats following abstinence: effect of naltrexone and changes in mu-opioid receptor density. Alcohol Clin Exp Res 23(6):1008–1014 PubMed PMID: 10397284
151. Overstreet DH, Kampov-Polevoy AB, Rezvani AH, Braun C, Bartus RT, Crews FT (1999) Suppression of alcohol intake by chronic naloxone treatment in P rats: tolerance development and elevation of opiate receptor binding. Alcohol Clin Exp Res 23(11):1761–1771 PubMed PMID: 10591592
152. Parkes H, Sinclair JD (2000) Reduction of alcohol drinking and upregulation of opioid receptors by oral naltrexone in AA rats. Alcohol 21(3):215–221 PubMed PMID: 11091024
153. Rodd-Henricks ZA, McKinzie DL, Shaikh SR, Murphy JM, McBride WJ, Lumeng L, Li TK (2000) Alcohol deprivation effect is prolonged in the alcohol preferring (P) rat after repeated deprivations. Alcohol Clin Exp Res 24(1):8–16 PubMed PMID: 10656186
154. Agabio R, Carai MA, Lobina C, Pani M, Reali R, Vacca G, Gessa GL, Colombo G (2000) Development of short-lasting alcohol deprivation effect in sardinian alcohol-preferring rats. Alcohol 21(1):59–62 PubMed PMID: 10946158
155. Sabino V, Cottone P, Blasio A, Iyer MR, Steardo L, Rice KC, Conti B, Koob GF, Zorrilla EP (2011) Activation of sigma-receptors induces binge-like drinking in Sardinian alcohol-preferring rats. Neuropsychopharmacology 36(6):1207–1218 Epub 2011/02/25. doi: 10.1038/npp.2011.5. PubMed PMID: 21346735; PMCID: 3079320
156. Sabino V, Cottone P, Zhao Y, Iyer MR, Steardo L Jr, Steardo L, Rice KC, Conti B, Koob GF, Zorrilla EP (2009) The sigma-receptor antagonist BD-1063 decreases ethanol intake and reinforcement in animal models of excessive drinking. Neuropsychopharmacology 34(6):1482–1493 Epub 2008/10/24. doi: 10.1038/npp.2008.192. PubMed PMID: 18946467; PMCID: 2669694
157. Sabino V, Cottone P, Koob GF, Steardo L, Lee MJ, Rice KC, Zorrilla EP (2006) Dissociation between opioid and CRF1 antagonist sensitive drinking in Sardinian alcohol-preferring rats. Psychopharmacology 189(2):175–186
158. Funk CK, O’Dell LE, Crawford EF, Koob GF (2006) Corticotropin-releasing factor within the central nucleus of the amygdala mediates enhanced ethanol self-administration in withdrawn, ethanol-dependent rats. J Neurosci 26(44):11324–11332
159. O’Dell L, Roberts AJ, Smith RT, Koob GF (2004) Enhanced alcohol self-administration after intermittent versus continuous alcohol vapor exposure. Alcohol Clin Exp Res 28:1676–1682
160. Vendruscolo LF, Roberts AJ (2014) Operant alcohol self-administration in dependent rats: focus on the vapor model. Alcohol 48(3):277–286
161. Martin-Fardon R, Weiss F (2013) Modeling relapse in animals. Curr Top Behav Neurosci 13:403–432. doi:10.1007/7854_2012_202 PubMed PMID: 22389178
162. Everitt BJ, Robbins TW (2000) Second-order schedules of drug reinforcement in rats and monkeys: measurement of reinforcing efficacy and drug-seeking behaviour. Psychopharmacology 153(1):17–30 Epub 2001/03/21. PubMed PMID: 11255926
163. Le A, Shaham Y (2002) Neurobiology of relapse to alcohol in rats. Pharmacol Ther 94(1–2):137–156 PubMed PMID: 12191599
164. Martin-Fardon R, Strong EM, Weiss F (2012) Effect of sigma(1) receptor antagonism on ethanol and natural reward seeking. Neuroreport 23(14): 809–813. doi:10.1097/WNR.0b013e32835717c8 PubMed PMID: 22878224
165. Velazquez-Sanchez C, Santos JW, Smith KL, Ferragud A, Sabino V, Cottone P (2015) Seeking behavior, place conditioning, and resistance to conditioned suppression of feeding in rats intermittently exposed to palatable food. Behav Neurosci 129(2):219–224. doi:10.1037/bne0000042 PubMed PMID: 25798634
166. Giuliano C, Goodlett CR, Economidou D, Garcia-Pardo MP, Belin D, Robbins TW, Bullmore ET, Everitt BJ (2015) The novel mu-opioid receptor antagonist GSK1521498 decreases both alcohol seeking and drinking: evidence from a new preclinical model of alcohol seeking. Neuropsychopharmacology 40(13):2981–2992. doi:10.1038/npp.2015.152 PubMed PMID: 26044906
167. Pitel AL, Beaunieux H, Witkowski T, Vabret F, Guillery-Girard B, Quinette P, Desgranges B, Eustache F (2007) Genuine episodic memory deficits and executive dysfunctions in alcoholic subjects early in abstinence. Alcohol Clin Exp Res 31(7):1169–1178. doi:10.1111/j.1530-0277.2007.00418.x PubMed PMID: 17511749; PMCID: 2895973
168. Beatty WW, Katzung VM, Moreland VJ, Nixon SJ (1995) Neuropsychological performance of recently abstinent alcoholics and cocaine abusers. Drug Alcohol Depend 37(3):247–253 PubMed PMID: 7796719
169. McKeon A, Frye MA, Delanty N (2008) The alcohol withdrawal syndrome. J Neurol Neurosurg Psychiatry 79(8):854–862. doi:10.1136/jnnp.2007.128322 PubMed PMID: 17986499
170. Koob GF (2003) Alcoholism: allostasis and beyond. Alcohol Clin Exp Res 27(2):232–243 Epub 2003/02/27. doi: 10.1097/01.ALC.0000057122.36127.C2. PubMed PMID: 12605072
171. Koob GF (2000) Animal models of craving for ethanol. Addiction 95(Suppl 2):S73–S81
172. Epub 2000/09/26. PubMed PMID: 11002904
173. Meunier J, Demeilliers B, Célérier A, Maurice T (2006) Compensatory effect by sigma1 (σ 1) receptor stimulation during alcohol withdrawal in mice performing an object recognition task. Behav Brain Res 166(1):166–176
174. Sabeti J, Gruol DL (2008) Emergence of NMDAR-independent long-term potentiation at hippocampal CA1 synapses following early adolescent exposure to chronic intermittent ethanol: role for sigma-receptors. Hippocampus 18(2):148–168
175. Jenner P, Marsden CD, Thanki CM (1978) Behavioural changes induced by N,N-dimethyltryptamine in rodents [proceedings]. Br J Pharmacol 63(2):380 P PubMed PMID: 276408; PMCID: 1668344
176. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101(2):131–181. doi:10.1016/j.pharmthera.2003.11.002 PubMed PMID: 14761703
177. Holtzman SG (1989) Opioid- and phencyclidine-like discriminative effects of ditolylguanidine, a selective sigma ligand. J Pharmacol Exp Ther 248(3):1054–1062 PubMed PMID: 2539453
178. Narita M, Yoshizawa K, Aoki K, Takagi M, Miyatake M, Suzuki T (2001) A putative sigma1 receptor antagonist NE-100 attenuates the discriminative stimulus effects of ketamine in rats. Addict Biol 6(4):373–376. doi:10.1080/13556210020077091 PubMed PMID: 11900615
179. Gambelunghe C, Aroni K, Rossi R, Moretti L, Bacci M (2008) Identification of N,N-dimethyltryptamine and beta-carbolines in psychotropic ayahuasca beverage. Biomed Chromatogr 22(10):1056–1059. doi:10.1002/bmc.1023 PubMed PMID: 18506697
180. Saavedra JM, Axelrod J (1972) Psychotomimetic N-methylated tryptamines: formation in brain in vivo and in vitro. Science 175(4028):1365–1366 PubMed PMID: 5059565
181. Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51(2):98–108 PubMed PMID: 8297217
182. Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE (2009) The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 323(5916):934–937. doi:10.1126/science.1166127 PubMed PMID: 19213917; PMCID: 2947205
183. Su TP, Hayashi T, Vaupel DB (2009) When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor. Sci Signal 2(61):pe12 Epub 2009/03/13. doi: scisignal.261pe12 [pii] 10.1126/scisignal.261pe12. PubMed PMID: 19278957